Objectives: A 12-week post-marketing study was conducted to provide real-world data on Japanese patients with overactive bladder (OAB) initiating treatment with mirabegron. This post-hoc analysis focused on safety and effectiveness of mirabegron in patients aged ≥75 versus <75 years.
other anticholinergic drugs. 20 In addition, antimuscarinics are known to affect the central nervous system in patients aged ≥65 years leading to cognitive dysfunction 21 and dementia. 22 Mirabegron is a first-in-class, β3-adrenoceptor agonist that enhances the relaxation of detrusor smooth muscle and increases storage capacity without affecting voiding ability. [23] [24] [25] [26] Notably, mirabegron has a favorable tolerability profile and an improved benefit-to-risk ratio compared with antimuscarinics in patients with OAB aged ≥65 years. 27, 28 Recently, we conducted a 12-week post-marketing study on Japanese patients with OAB initiating treatment with mirabegron in a routine clinical setting. 29 Interestingly, the proportion of patients aged ≥65 years was >80%, which was higher than that reported in Japanese clinical studies, 30, 31 and nearly half of the patients (48.8%) were ≥75 years old. Most developed nations have termed the chronological age of 65 years as "elderly." 32 Considering, however, the continuous improvement in health, cognition and functional independence of the aging population, an increase in the cut-off chronological age from 65 to 75 years has been proposed to describe "elderly". 33, 34 Therefore, we conducted a post-hoc analysis of patients with OAB aged ≥75 years versus those aged <75 years to determine the safety and treatment effectiveness of mirabegron in a routine clinical setting.
| METHODS

| Survey methods and participants
The study was conducted from April 2012 to July 2014 in compliance with Good Post-Marketing Study Practice (GPSP). The primary findings of the study together with the methodology have been published elsewhere. 29 Briefly, patients who were prescribed mirabegron for OAB with symptoms of urgency, urinary frequency and urge incontinence, and who had not been previously treated with mirabegron, were eligible for inclusion in the study. Data were collected via the internet-based post-marketing survey data collection system. Physicians registered each patient within 14 days of the start of mirabegron treatment (not including the start date of treatment) and entered data for all registered patients at the end of the 12-week observation period or at discontinuation.
| Patient assessments
Patient assessment has been described in detail earlier. 29 All adverse events (AE; including adverse drug reactions [ADR] and abnormal laboratory values or other test values) that had occurred during treatment or after the completion of treatment with mirabegron were coded using system organ class (number of patients) and preferred term (number of events) in Japanese MedDRA version 17.1.
Based on changes in OAB symptoms from baseline to the end of treatment (end of treatment at week 12 or at the time of discontinuation), physicians evaluated efficacy as 'effective', 'ineffective', or 'not evaluable'. Reasons for considering the symptoms 'not evaluable' were recorded. OAB symptoms were assessed using the Overactive Bladder Symptom Score (OABSS) at baseline and at the end of treatment. A reduction of ≥3 points in total score was defined as a minimal clinically important change (MCIC). 35 Patients who achieved a ≥1-point (s) reduction in total OABSS score from baseline were rated as improved. Total OABSS was further classified as 'mild', score 0 to 5;
'moderate', score 6 to 11; and 'severe', score 12 to 15. OABSS subscores included questions on daytime frequency (3-point scale), nocturia (4-point scale), urgency (6-point scale), and urge incontinence (6-point scale). Change in QoL from baseline to the end of treatment was assessed by the International-Prostate Symptom Score Quality of Life (I-PSS QoL). Patients who achieved a ≥1-point(s) reduction in I-PSS QoL score from baseline were rated as improved. Based on the severity of QoL, I-PSS QoL was further classified as 'mild', score 0 or 1; 'moderate', score 2 to 4; and 'severe', score 5 or 6.
| Statistical analysis
As reported previously, 29 the safety analysis set (SAF) included patients who received ≥1 dose of mirabegron and had at least one study visit after initial administration. The efficacy analysis set consisted of patients who were diagnosed with OAB and who were eligible for efficacy assessment by the attending physician. The OABSS analysis set included patients from the efficacy analysis set if they did not have concurrent diseases excluded for OAB diagnosis, were judged to have OAB based on the OABSS definition (OABSS question 3 score ≥2 points and total OABSS ≥3 points), received mirabegron according to the dosing regimen, and completed the OABSS at baseline and at the end of treatment without missing data.
Fisher's exact test was used for the statistical analysis of two stratified groups and the Cochran-Armitage test was used if three or more stratified groups were present and if variables had ordered categories. Wilcoxon signed-rank test was used for testing the difference from baseline during the observation period. Statistical tests were two-sided and P < 0.05 was defined as statistically significant.
| RESULTS
| Patient disposition and baseline characteristics
A total of 10 711 patients were registered for the study and data were collected from 10 688 patients across 1111 medical institutions.
Following the exclusion of 893 patients, 9795 patients were included in the SAF and 9792 patients were included in the efficacy analysis set. A total of 4153 patients from the efficacy analysis set were eligible for inclusion in the OABSS analysis set. The SAF, efficacy and OABSS analysis sets were further stratified into two groups, consisting of patients aged ≥75 and <75 years ( Figure 1 ).
Significant differences were noted in baseline characteristics and demographics between the two age groups (Table 1 ). More than half of the patients in the SAF aged ≥75 years were men (50.5%, n = 2418), which was significantly greater than the proportion of male patients aged <75 years (43.3%, n = 2170, P < 0.001). Among men, a mean prostate volume ≥ 50 mL was observed in 7.1% (n = 172) of patients aged ≥75 years compared with 6.2% (n = 134) of patients aged <75 years. Moreover, increase in prostate volume was found to be positively associated with advancing age: a greater proportion of patients aged ≥75 years than those aged <75 years were found to have higher prostate volume. This difference between the two age groups was statistically significant in the SAF (P = 0.004), but not in the OABSS analysis set (P = 0.527). Bodyweight and subsequently, the body mass index (BMI) decreased with age: in the SAF, 4.2%
(n = 199) of patients aged ≥75 years compared with 3.2% (n = 159) aged <75 years were underweight (BMI < 18.5). In addition, a lower proportion of patients aged ≥75 years than those aged <75 years had a higher BMI (P < 0.001).
Regarding OAB status, disease duration and severity increased with age: a higher percentage of patients in the SAF aged ≥75 years were diagnosed with OAB longer than 3 years (24.6% vs 20.3%) and had more severe symptoms than patients aged <75 years (17.0% vs 11.2%). Additionally, a significant increase in incontinence was observed in patients aged ≥75 years compared with those aged <75 years (64.3% vs 59.4%, P < 0.001). Advancing age was also associated with increased residual urine volume: a baseline volume of ≥50 to <100 mL was observed in 7.9% of patients aged ≥75 years and in 6.0% of those aged <75 years. Furthermore, a significantly greater proportion of patients aged ≥75 years compared with those aged <75 years had a higher residual urine volume (P < 0.001).
In the SAF, the presence of concurrent diseases was significantly higher in patients aged ≥75 years than in those aged <75 years (77.8%
vs 66.0%, P < 0.001; Table 2 ). The major concurrent diseases (reported in ≥3.0% of patients) were similar in both age groups. A greater proportion (difference ≥ 2.0%), however, of patients aged ≥75 years compared with those aged <75 years, had prostatic hyperplasia (male patients only), hypertension, constipation, prostate cancer, angina pectoris, arrhythmia, and osteoporosis. In addition, 29.0% of patients aged ≥75 years, in contrast to 24.6% aged <75 years, had a medical history (P < 0.001). Finally, patient histories indicated the prevalence of polypharmacy among elderly patients. More than half of the patients in the SAF aged ≥75 years (58.3%) were treated with concomitant drugs, which was significantly greater than 48.7% of those aged <75 years (P < 0.001). The major drug categories reported by ≥3.0% of patients aged ≥75 years included α 1 -blockers, anticholinergic agents, and 5α-reductase inhibitors. In addition, the use of specified drugs -amlodipine besylate, magnesium oxide, and aspirin -was reported by ≥2.0% of patients aged ≥75 years. Importantly, these drugs were used by a greater proportion (difference ≥ 1.0%) of patients aged ≥75 years compared with those aged <75 years. Similar observations were noted in the use of concomitant drugs in the OABSS analysis set (data not shown).
| Incidence of adverse drug reactions
A total of 388 ADR were reported in 335 of 4784 patients in the SAF aged ≥75 years compared with 294 ADR observed in 260 of 5011 patients aged <75 years (7.00% vs 5.19%, respectively, P < 0.001; Table 3 ). Although the type of major ADR was similar in both the groups, a higher percentage (difference ≥ 0.1%) of patients aged ≥75 years compared with those aged <75 years had residual urine volume increased, dysuria, thirst, dizziness, urinary retention, cystitis, and urinary tract infection, which were mostly lower urinary tract obstructive events. In contrast, the incidence of palpitations occurred at a higher incidence in patients aged <75 years than in those aged ≥75 years (12 events vs five events). 2) n/a n/a n/a n/a 
| Efficacy
Mirabegron treatment was reported to be effective at the end of treatment in 79.3% (n = 3630) of patients aged ≥75 years in the efficacy analysis set. This was statistically significantly lower than the efficacy rate of mirabegron in patients aged <75 years (82.1%, n = 3952, P < 0.001). In the OABSS analysis set, mirabegron was 'effective' in approximately 85% of patients and there was no significant difference between the age groups (n = 1635, 84.8% and n = 1883, 86.6% in patients aged ≥75 years and <75 years, respectively; P = 0.098).
Mirabegron alleviated OAB symptoms over the course of treatment in both groups (Table 4) . Although the change (mean AE SD) in total OABSS from baseline to the end of treatment in patients aged ≥75 years was statistically significantly lower than that reported in patients aged <75 years (−3.6 AE 3.22 vs −3.8 AE 3.01, P = 0.002), this change exceeded the MCIC in both groups. In terms of individual patient outcome, MCIC achievement rate in patients aged ≥75 years was 61.0%, which was statistically significantly lower than that in patients aged <75 years (65.9%, P < 0.001). Total OABSS at the end of treatment, however, was rated as improved (a ≥1-point(s) reduction in total OABSS score from baseline) in >80% of patients in both age groups (82.6% and 85.3% of patients aged ≥75 and <75 years, respectively). Additionally, a significant reduction was reported in all four symptom subscores in both groups (P < 0.001 for each subscore).
Based on total OABSS, symptom severity of OAB was found to improve with mirabegron treatment. The majority of patients in both age groups experienced moderate or severe symptoms at baseline (71.2% and 23.5% in patients aged ≥75 years; 75.8%, and 14.3% in patients aged <75 years, respectively; Figure 2 ). By the end of treatment, however, a shift towards mild or moderate symptoms was observed (50.7% and 42.7% in patients aged ≥75 years; 64.5% and 32.0% in patients aged <75 years, respectively). Only 6.6% and 3.5% of patients aged ≥75 and <75 years, respectively were rated as having severe symptoms at the end of treatment. Importantly, compared with baseline, the percentage of patients with less severe symptoms was statistically significantly higher in both groups at the end of treatment (P < 0.001). Change by end of treatment Table 5 ), >75% of patients in both groups were rated as improved (a ≥1-point(s) reduction in I-PSS QoL score from baseline; 76.8% and 79.9% of patients aged ≥75 and <75 years, respectively). Additionally, at baseline, I-PSS QoL was found to be severe in 71.8% of patients aged ≥75 years and in 76.1% aged <75 years, but by the end of treatment, fewer patients experienced severe symptoms (19.1% and 17.6%, respectively; Figure 3 ). Moreover, compared with baseline, a significant increase in the percentage of patients with less severe symptoms was observed in both groups at the end of treatment (P < 0.001).
| DISCUSSION
Overactive bladder is a distressing condition that becomes increasingly more prevalent with advancing age. Mirabegron, a β3-adrenoceptor agonist with bladder-specific action, has been considered a favorable treatment option for OAB, particularly among the aging population. [23] [24] [25] 28, 36 Here we report the first large-scale postmarketing evaluation on safety and effectiveness of mirabegron in Japanese patients with OAB aged ≥75 years.
Aging is a non-uniform process. 34 Subsequently, considerable heterogeneity was observed in the patient baseline demographic characteristics in the current survey. Elderly patients aged ≥75 years had lower bodyweight and BMI than their younger counterparts. The data suggest that elderly patients aged ≥75 years might be frail. In recent years, increasing scientific interest has developed regarding the concept of "frailty," which is defined as a state of vulnerability associated with impaired physical activity, mobility, cognition, nutrition, and endurance. 37, 38 The frail aging population is exposed to increased risk of comorbidity, disability, and hospitalization. 6, 38 Moreover, frailty has been associated with medical complexity and polypharmacy, 39, 40 which in turn may aggravate urinary symptoms or underlying bladder conditions, leading to adverse events. 39, 41 In line with these reports, we observed a higher rate of concurrent diseases and subsequent use of concomitant medication in elderly patients aged ≥75 years compared with those aged <75 years.
Treatment options for patients with OAB and uncontrolled narrow angle glaucoma are limited because antimuscarinics are known to increase intraocular pressure. 42 Mirabegron has a different mechanism of action from antimuscarinics and has been shown not to alter intraocular pressure. 43 The prevalence of glaucoma among Japanese adults aged ≥40 years is 3.9% to 5.0%. 44, 45 The present study, which was conducted in a routine clinical setting, included 2.7% and 3.6% of patients aged <75 years and ≥75 years, respectively, with concurrent glaucoma, suggesting that mirabegron is a well-tolerated treatment for patients with OAB and glaucoma.
Previously reported Japanese post-marketing studies on the safety of antimuscarinics in patients aged ≥65 years noted an incidence of ADR of 11.68% with tolterodine, and of 15.00% with solifenacin. 46, 47 Furthermore, a correlation was observed between advancing age and increasing incidence of ADR related to these antimuscarinics. The overall incidence of ADR associated with mirabegron in the current study was 7.00% in patients aged ≥75 years, which was significantly higher than in those aged <75 years (5.19%). There was no marked difference in the type of major ADR between the two age groups. The incidence of ADR related to lower urinary tract obstructive events (urinary retention, dysuria, and residual urine volume increase), however, was higher in the elderly patients aged ≥75 years than in those aged <75 years. The difference could be explained by the fact that the elderly group had a higher proportion of men, the majority of whom had benign prostatic hyperplasia. 29 Moreover, the medical consultation rate has been reported to be higher in men than in women. 9 Additionally, clinical urodynamic studies have
shown that aging may contribute to reduced bladder capacity, increased uninhibited contractions, decreased urinary flow rate, diminished urethral pressure, and increased post-void residual urine volume. 48 These findings may contribute to the higher incidence of lower urinary tract obstructive events in patients aged ≥75 years.
Finally, this study evaluated the efficacy of mirabegron in elderly patients in a real-world clinical setting without the limitations imposed by clinical trials. At the end of treatment, mirabegron was found to be effective in approximately 80% of patients with OAB. Although there was no significant difference between the two age groups in the OABSS analysis set, mirabegron had reduced efficacy in patients aged ≥75 years in the efficacy analysis set. At baseline, the elderly patients had longer disease duration and more complicated medical condition than those aged <75 years. This may lead to severe OAB symptoms and incontinence, which, in turn, may contribute to the poorer level of efficacy observed in this group. Similar age-related reduction in efficacy was observed in the earlier post-marketing study on solifenacin and tolterodine in patients aged ≥65 years. 46, 47 Nevertheless, in this survey, total OABSS achieved MCIC, and significant improvements were observed in all four symptom subscores in both age groups. Furthermore, analysis of symptom severity and individual symptom changes (OABSS/I-PSS QoL severity) showed that the proportion of patients with milder symptoms increased across all age groups following mirabegron treatment.
Based on a survey of real-world patients, a potential limitation of the current study is the lack of a placebo control. In addition, the study faces the inherent challenges related to post-hoc analyses and loss of randomization. 49 Moreover, cardiovascular disorders and cognitive side-effects, which increase with advancing age, need to be investigated in greater detail.
| CONCLUSION
Elderly patients aged ≥75 years had lower BMI, more comorbidities and higher concomitant drug use compared with patients aged <75 years. In addition, the elderly patients had more severe OAB and longer disease duration. In a real-world clinical setting, however, mirabegron was well-tolerated and effective in elderly patients. 
